 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...1112131415161718192021...7475» |
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Real world outcomes of Retinopathy of prematurity treatment with Anti-vascular endothelial growth factor versus Laser therapy in Singapore (Main Room) - May 25, 2022 - Abstract #Macula2022Macula_239;
These findings suggest Type 1 ROP treated with primary anti-VEGF therapy had better outcomes with less progression to stage 4 or worse compared with those that received primary laser therapy. However, these babies require longer followup for recurrences.
- Lucentis (ranibizumab) / Roche, Novartis
Quantitative Analyses of Geographic Atrophy, Drusen, and Macular Dimensions in the Prophylactic Ranibizumab in Fellow Vulnerable High-Risk Eyes with Nonexudative AMD in Patients with Exudative AMD in One Eye (PREVENT) Trial (Main Room) - May 25, 2022 - Abstract #Macula2022Macula_92;
However, these babies require longer followup for recurrences. Despite no reduction of neovascular conversion with Q3M ranibizumab for eyes with intermediate AMD, secondary analyses showed no accelerated changes in GA, drusen or macular dimensions compared to sham eyes over 24M.
- Lucentis (ranibizumab) / Roche, Novartis
Development of a short form of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) (Main Room) - May 25, 2022 - Abstract #Macula2022Macula_30;
This study applied quantitative item reduction methodology to reduce the NEI VFQ-25 from 25 to 7 items. The resulting questionnaire, the VFQ-SF, demonstrated robust psychometric properties that supports its use in place of the NEI VFQ-25 to generate a composite vision-related functioning score in nAMD patients when time is limited.
- || JNJ-1887 / J&J
Trial completion: AAVCAGsCD59 for the Treatment of Wet AMD (clinicaltrials.gov) - May 25, 2022
P1, N=25, Completed, Sponsor: Janssen Research & Development, LLC
The resulting questionnaire, the VFQ-SF, demonstrated robust psychometric properties that supports its use in place of the NEI VFQ-25 to generate a composite vision-related functioning score in nAMD patients when time is limited. Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
The management of neovascular glaucoma: a systematic review and meta analysis of randomised controlled trials (Poster Area) - May 24, 2022 - Abstract #EGS2022EGS_533;
The lack of high-quality evidence contributes to the lack of consensus in managing NVG. Our results highlight modern treatment strategies and the need for better powered RCTs with long-term follow-up in order to establish optimal treatment modalities and true patient Outcomes.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity. (Pubmed Central) - May 24, 2022
The regression of AP-ROP is significantly lower than type 1 pre-threshold and threshold disease. Birth weight, retinal hemorrhage, iris neovascularization or vascular engorgement and lesions located in zone I may be associated with AP-ROP recurrence and retreatment, which should be noted in follow-up.
- | Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy (clinicaltrials.gov) - May 23, 2022
P4, N=96, Recruiting, Sponsor: Ruijin Hospital
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Optical Coherence Tomography Combined with Fluorescein Fundus Angiography under Intelligent Algorithm to Evaluate the Clinical Efficacy of Ranibizumab Combined with Panretinal Photocoagulation in the Treatment of Macular Edema of Diabetic Retinopathy Patients. (Pubmed Central) - May 22, 2022
With the increase of the grade of fibrous proliferation and the grade of bleeding, the operation time, the number of electrocoagulation, and the possibility of iatrogenic holes of patient would increase. It can be known that ranibizumab combined with panretinal photocoagulation surgery could not only reduce the macular edema but also effectively reduce the intraoperative bleeding, simplify the removal of proliferative membranes, decrease the number of electrocoagulation, and shorten the operation time, enhancing the visual function of patients.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration. (Pubmed Central) - May 19, 2022
No factor was found to be associated with final CMT. Although the final visual outcome is limited by the progression of the disease, hemorrhagic lesions treated with ranibizumab have stable anatomical outcome.
- || Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Clinical, Journal: The prognostic role of optical coherence tomography in diabetic macular edema patients undergoing early dexamethasone implant shift. (Pubmed Central) - May 19, 2022
To determine the prognostic characteristics of optical coherence tomography (OCT) parameters by evaluating diabetic macular edema (DME) patients with early dexamethasone (DEX) shift after three doses of intravitreal ranibizumab (RNB) injection...(sensitivity 70%, specificity 84% area under the curve 0.817, p = 0.021). The presence of high number of HRS and high subretinal fluid volume at the baseline negatively affect prognosis even in patient groups with early DEX shift.
- | Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Journal: Evaluation of retinal inflammatory biomarkers after intravitreal steroid implant and Ranibizumab injection in diabetic macular edema. (Pubmed Central) - May 19, 2022
HRSs tended to migrate from inner retina to the outer retina in DME eyes by treatment. Dexamethasone seemed to be more effective option in such cases with inflammatory component.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study). (Pubmed Central) - May 19, 2022
The difference in total treatment cost is largely explained by the significantly lower frequency of IVI and annual cost of therapy with DXI, compared with AFL and RAN. INVICOST is the first study comparing treatment costs with AFL, DXI and RAN in France in current clinical practice.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: New trends in intravitreal anti-VEGF therapy for ROP. (Pubmed Central) - May 19, 2022
The recurrence rate stands at an average of 28.9%, especially in the later forms of ROP. Using a dose of 0.25 mg of Conbercept, the disease regression rate is currently on average 83%, with an average recurrence rate of 15.24%, the peak of which was observed in cases of ROP in zone I. Further studies are needed to prove safety at long term, because,at the moment, only short-term data are available.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Estimating ranibizumab injection numbers and visual acuity at 12 months based on 2-month data on branch retinal vein occlusion treatment. (Pubmed Central) - May 18, 2022
The correlation coefficients for VA scores at Months 2 and 12 were 0.60 and 0.51 for the monotherapy and combination groups, respectively (both p < 0.01). Based on VA and injection numbers at Month 2 of treatment, physicians could provide rough prospects on patients' expected final VA and required number of injections.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Real-life results in treating neovascular age-related macular degeneration with anti-VEGF therapy. Analysis of 122 patients from a single centre. (Pubmed Central) - May 13, 2022
The treatment has demonstrated its efficacy by improving visual acuity and central macular thickness. However, the number of injections performed has generally been higher than in other real-life studies.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-world evidence: Real-world outcomes of anti-VEGF therapy in treatment-naïve neovascular age-related macular degeneration diagnosed on OCT angiography: the REVEAL study. (Pubmed Central) - May 12, 2022
However, the number of injections performed has generally been higher than in other real-life studies. In a real-world setting, nAMD patients diagnosed with OCT-A showed meaningful improvements in visual and anatomical parameters during 12 months of treatment, without significant differences with those diagnosed by invasive modalities.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: 12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry. (Pubmed Central) - May 12, 2022
In a real-world setting, nAMD patients diagnosed with OCT-A showed meaningful improvements in visual and anatomical parameters during 12 months of treatment, without significant differences with those diagnosed by invasive modalities. Both aflibercept and ranibizumab improved VA and reduced CST in eyes with CRVO in routine clinical practice, with aflibercept showing significantly greater improvements in this comparative analysis.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal, Monotherapy: Pachychoroid-phenotype effects on 5-year visual outcomes of anti-VEGF monotherapy in polypoidal choroidal vasculopathy. (Pubmed Central) - May 12, 2022
Both aflibercept and ranibizumab improved VA and reduced CST in eyes with CRVO in routine clinical practice, with aflibercept showing significantly greater improvements in this comparative analysis. Our findings suggest that anti-VEGF monotherapy was similarly effective for pachychoroid- and non-pachychoroid-phenotype eyes with PCV, for at least 5 years, although further studies are required.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Review, Journal: Frequency of intravitreal anti-vascular endothelial growth factor injections and risk of death: a systematic review with meta-analysis. (Pubmed Central) - May 12, 2022
No significant influence of anti-VEGF treatment intensity on mortality was shown, supporting a message of reassurance over safety concerns of this therapy. Marginal evidence of a higher risk associated with a more intense treatment was found in patients with DME.
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: CoRaLa II: Combination of Ranibizumab and Targeted Laser Photocoagulation (clinicaltrials.gov) - May 11, 2022
P3, N=110, Recruiting, Sponsor: University of Giessen
Marginal evidence of a higher risk associated with a more intense treatment was found in patients with DME. Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- | Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: OPHTH-010915: Aflibercept in Recurrent or Persistent CNV (clinicaltrials.gov) - May 9, 2022
P=N/A, N=80, Recruiting, Sponsor: Medical University of Vienna
Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- | Beovu (brolucizumab-dbll) / Novartis, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal, HEOR: Treatment of Neovascular Age-Related Macular Degeneration: An Economic Cost-Risk Analysis of Anti-VEGF agents. (Pubmed Central) - May 6, 2022
Since medical advances and different costs may change our findings, we provide a free application (https://eye-inj.shinyapps.io/calc/) for readers who wish to use different cost structures. Simulating outcomes is an innovative approach, unique in ophthalmology, and presents significant opportunity as it can be easily adapted to different settings (using different costs, risks, and protocols), and to other diseases (e.g., DME), to ultimately improve wide-scale decision-making and use of funds.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Structural and vascular changes of the choroid in polypoidal choroidal vasculopathy after intravitreal anti-VEGF therapy. (Pubmed Central) - May 6, 2022
The close relationship between the thinner SFCT and better visual outcome after LP reveals the role of the EDI-OCT assessment of the choroid as a predictive biomarker of functional response to anti-VEGF therapy. This tool could provide a quantitative evaluation of structural features of the choroid avoiding mistakes of evaluation at OCTA.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion. (Pubmed Central) - May 6, 2022
Treatment patterns and outcomes for nAMD, DMO and RVO in routine clinical practice have stabilised over the past 5 years at levels inferior to those reported by the pivotal phase 3 studies. A conscious effort to treat these conditions more intensively, or with longer lasting agents, would likely improve outcomes further in our patients.
- Humira (adalimumab) / Eisai, AbbVie
Ocular Pharmacokinetics of Recombinant and AAV Mediated Expression of Adalimumab After Intravitreal Injection in Mice (Poster Board Number: Tu-52; Hall D) - May 6, 2022 - Abstract #ASGCT2022ASGCT_1680;
Rev.). Although mice are a common species for preclinical evaluation of drug response, the rapid clearance from the eye and systemic accumulation may confound interpretation of safety and efficacy of AAV gene therapies expressing a secreted protein.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Renal Function Impairment in Diabetic Patients after Intravitreal Injection of Anti-Vascular endothelial Growth Factor (Mini-Orals Hall) - May 5, 2022 - Abstract #ERAEDTA2022ERA_EDTA_998;
CONCLUSION A significant decrease in eGFR and an increase in proteinuria are observed after administration of anti-VEGF in diabetic patients. For this reason, a close monitoring of renal function is needed to establish an early diagnosis and management of possible complications.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: INTRAVITREAL RANIBIZUMAB IN PREGNANT PATIENT WITH MYOPIC CHOROIDAL NEOVASCULAR MEMBRANE. A CASE REPORT. (Pubmed Central) - May 5, 2022
However, it is always necessary to consider the risk/benefit ratio when administering intravitreal antiVEGF drugs in pregnant patients. Thorough discussion with the patient is necessary.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Factors predicting the treatment frequency of ranibizumab injections during the second year in diabetic macular edema. (Pubmed Central) - May 3, 2022
Thorough discussion with the patient is necessary. The cumulative doses of ranibizumab injections, CST, and hyperreflective walls in the foveal cystoid spaces at the 12-month visit are designated predictors of the treatment frequency of ranibizumab injections during the second year in DME.
- | Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Retrospective data, Journal: Neovascular Remodeling and Subretinal Fibrosis as Biomarkers for Predicting Incomplete Response to Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration. (Pubmed Central) - May 3, 2022
The progression of neovascular remodeling and subretinal fibrosis may serve as biomarkers to predict incomplete response to anti-VEGF therapy in patients with NVAMD. Subretinal fibrosis complicating NVAMD remains a major obstacle for the management of NVAMD, and anti-VEGF treatment is a potential therapeutic strategy to target neovascular remodeling and subretinal fibrosis as either an additive or alternative therapeutic approach for NVAMD.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: A ranibizumab ocular implant (Susvimo) for age-related macular degeneration. (Pubmed Central) - May 3, 2022
Subretinal fibrosis complicating NVAMD remains a major obstacle for the management of NVAMD, and anti-VEGF treatment is a potential therapeutic strategy to target neovascular remodeling and subretinal fibrosis as either an additive or alternative therapeutic approach for NVAMD. No abstract available
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Intestinal perforation after intravitreal low dose ranibizumab injection for the treatment of type 1 retinopathy of prematurity: A case report. (Pubmed Central) - May 3, 2022
No abstract available The risk of GIS perforation should be taken into consideration during the application of intravitreal vascular endothelial growth factor antagonist agents, especially in newborns with previous GIS surgery and a history of NEC, and these patients should be carefully monitored for GIS complications.
- || Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: RAZORBILL: A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (clinicaltrials.gov) - May 2, 2022
P=N/A, N=720, Recruiting, Sponsor: Novartis Pharmaceuticals
The risk of GIS perforation should be taken into consideration during the application of intravitreal vascular endothelial growth factor antagonist agents, especially in newborns with previous GIS surgery and a history of NEC, and these patients should be carefully monitored for GIS complications. N=424 --> 720
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Comparison of Choroidal Thickness, Foveal Avascular Zone, and Macular Capillary Density in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Ranibizumab or Aflibercept-A Prospective Study. (Pubmed Central) - May 1, 2022
OCTA offered further qualitative and quantitative evaluation of treatment-naïve BRVO. Judging by OCTA parameters, not only in the diseased eye but also in the fellow eye, DCP density of BRVO sectors was the most predictive factor of final visual outcome.
- || Razumab (ranibizumab biosimilar) / Intas, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study). (Pubmed Central) - Apr 30, 2022
Judging by OCTA parameters, not only in the diseased eye but also in the fellow eye, DCP density of BRVO sectors was the most predictive factor of final visual outcome. No abstract available
- | Beovu (brolucizumab-dbll) / Novartis
Retrospective data, Journal: Short-term outcomes after interim treatment with brolucizumab: a retrospective case series of a single center experience. (Pubmed Central) - Apr 29, 2022
Interim treatment with brolucizumab resulted in anatomical improvements in 41 eyes (41/51%, 80%) that were maintained in 22 of these eyes (22/41%, 54%) for at least 6 months after switching back to the original anti-vascular endothelial growth factor therapeutic. There were no corresponding significant changes in visual acuity.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Re-treatments after laser coagulation or anti-VEGF injections in infants treated for retinopathy of prematurity – data from the German ROP registry ([Virtual]) - Apr 29, 2022 - Abstract #ARVO2022ARVO_4828;
Re-treatment rates were higher after initial treatment with rbz and occurred later with rbz or bvz compared to laser. Real life data from registries can help adjusting treatment decisions and follow-up regimens in ROP.
- Avastin (bevacizumab) / Roche
Efficiency of anti-VEGF drug switch in patients who did not respond to a series of Bevacizumab injections ([Virtual]) - Apr 29, 2022 - Abstract #ARVO2022ARVO_4542;
We retrospectively compared the results of the central macular thickness (CMT) and visual acuity (VA) between eyes with sub-optimal response to at least three Bevacizumab injections that continued retreatment with Bevacizumab versus those that switched to Aflibercept or Ranibizumab injections. Our results may indicate that switching between anti-VEGF agents is indeed an effective strategy to treat eyes with sub-optimal response to Bevacizumab injections.
- Vabysmo (faricimab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration (nAMD) using machine learning (F0256) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3987;
P2
To fully understand advantages and limitations of this method, validation at a larger scale is warranted. Layman Abstract: Neovascular, or wet, age-related macular degeneration (nAMD for short), a common cause of sight loss in elderly people, is commonly treated with medicines that require regular injections (every 1 or 2 months) into the eye over a long period of time.
- Lucentis (ranibizumab) / Roche, Novartis
Machine learning approach to identify future treatment requirement in pretreated nAMD patients based on OCT images ([Virtual]) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3980;
P3
Further confirmation of model performance will contribute to future development of personalized health care algorithms. Images: Figure 1.
- Lucentis (ranibizumab) / Roche, Novartis
Morphological Biomarkers Related to Visual Acuity in Patients with Radiation Retinopathy Treated with Intravitreal Ranibizumab (A0025) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3818;
Larger, multicenter studies are needed to fully understand and monitor morphological changes affecting visual acuity changes in RR. Layman Abstract: This is a study examining detailed features of OCT images that may help predict which eyes will do bettter with anti-VEGF therapyt for radiation retinopathy.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Discontinuation, switching, and other long-term real-world treatment patterns among patients with diabetic macular edema initiating anti-VEGF: 6-year follow-up using the IRIS® Registry (F0249) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3797;
58% patients initially received bevacizumab, but its use decreased over time with an increased use of on-label agents. Reasons for switching and discontinuation should be further explored.
- Lucentis (ranibizumab) / Roche, Novartis
Machine learning approaches to automated prediction of fibrosis development in neovascular age-related macular degeneration using optical coherence tomography images (F0041) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3715;
P3
The DL-seg model, DL-raw model, and feature-based learning all achieved comparable performance in predicting fibrosis and were also comparable to the clinical variables only model, which requires invasive procedures and expert training for image interpretation (FA). These findings show that ML using OCT segmentations is a promising noninvasive approach to predicting fibrosis development in nAMD.
- Lucentis (ranibizumab) / Roche, Novartis
Vitrectomy after Anti-VEGF or Pan-retinal Photocoagulation Therapy in Proliferative Diabetic Retinopathy ([Virtual]) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3634;
Although median time to vitrectomy was longer for anti-VEGF monotherapy compared to PRP monotherapy, both treatment modalities had the same odds of ultimately requiring a vitrectomy. These results suggest that PRP does not increase the odds of vitrectomy compared to anti-VEGF in PDR patients.
- Lucentis (ranibizumab) / Roche, Novartis
Long-term effects of panretinal photocoagulation (PRP) vs intravitreal ranibizumab (IVR) on OCT-measured choroidal thickness, and retinal thickness and integrity (F0253) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3605;
Both study arms had significant decreases in superior and inferior choroidal thickness at 5 years. IVR had greater FCS thickness and TRV reductions than PRP.
- Lucentis (ranibizumab) / Roche, Novartis
Long-term effects of anti-VEGF therapy versus panretinal photocoagulation (PRP) on retinal vessel caliber in eyes with proliferative diabetic retinopathy (PDR) (F0255) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3604;
While most of the arteriolar narrowing occurred within the first 2 years for the PRP group, it occurred after 2 years in the RBZ group, suggesting that these treatments may affect the retinal vasculature at differential rates. Images:
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Development of neovascular glaucoma in severe diabetic retinopathy during follow-up treatment with anti-VEGF drugs treated with laser panphotocoagulation () - Apr 29, 2022 - Abstract #ARVO2022ARVO_3589;
The condition responds well to treatment with panretinal ablation and additional anti VEGF injections, but despite the rigorous treatment, the visual outcome is poor Layman Abstract: Diabetic retinopathy is a disease that affect up to 20% of diabetic patients. When severe cases settle, an even worse condition might develop: neovascular glaucoma, which can lead to blindness.
- Beovu (brolucizumab-dbll) / Novartis
Short-term efficacy of switch therapy to brolucizumab in Japanese patients with neovascular age-related macular degeneration ([Virtual]) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3148;
When severe cases settle, an even worse condition might develop: neovascular glaucoma, which can lead to blindness. The switch therapy to brolucizumab resulted in early anatomical response for Japanese patients with nAMD recalcitrant to aflibercept or ranibizumab therapy.
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Incidence, Risk Factors and Outcomes of Submacular Hemorrhage with Loss of Vision in Neovascular Age-Related Macular Degeneration in Daily Clinical Practice: the Fight Retinal Blindness! Registry (F0178) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3139;
SMH with loss of vision is an uncommon complication that can occur at any time in eyes treated for nAMD in routine clinical practice, with only limited recovery of vision one year later. Layman Abstract: Submacular hemorrhage with loss of vision is a rare and severe complication in eyes treated with intravitreal VEGF inhibitor for neovascular age-related macular degeneration in daily practice.
- Beovu (brolucizumab-dbll) / Novartis, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Efficacy of the Treat-and-Extend Regimen in the Management of Neovascular Age-related Macular Degeneration: 8-year Results of the RENO Study ([Virtual]) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3131;
The T&E regimen has been effective in maintaining visual acuity in nAMD patients treated with ranibizumab, aflibercept, bevacizumab, or brolucizumab for up to six years of treatment. Patients lost vision in the 7th and 8th year of treatment and further analysis is needed to evaluate the cause of vision loss.
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Does Intravitreal Anti-VEGF Therapy with Ranibizumab, Bevacizumab, and Aflibercept Cause Rebound Supranormal Systemic VEGF Levels? ([Virtual]) - Apr 29, 2022 - Abstract #ARVO2022ARVO_3130;
Paradoxically, plasma VEGF levels were sometimes much higher in treated individuals than in the control group suggesting an attempted homeostatic influence; this is of unknown significance. Perhaps there is up-regulation of systemic VEGF production in response to the anti-VEGF drug challenge.